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Introduction
The modern concept of targeted therapy in patients with
hematologic malignancies, and cancers in general, aims at gen-
erating new agents committed to targeting tumor cells more
specifically and with less toxicity than conventional chemo-
radiotherapy. Immunotherapy in general, and T-cell based
immunotherapies which are the specific focus of this review,
are excellent examples of these new agents. Physiologically, T
lymphocytes recognize antigens through a unique antigen-spe-
cific αβ-T cell receptor (TCR), promote the elimination of the
targeted antigen (effector function) and amplify the attack to
the antigen by recruiting other components of the immune
response (helper function). Although tumor specificity can be
accomplished clinically using monoclonal antibodies, T lym-
phocytes have additional critical properties that make their
clinical application attractive. T lymphocytes can, indeed,
actively biodistribute themselves within tissues and the tumor
environment, and have the potential for in vivo expansion and
self-maintenance, as they can establish a memory compart-
ment. New bi-specific antibodies also have the properties of
selective antigen specificity and T-cell activation.1 Although
preliminary clinical studies are very encouraging, the antitumor
effects provided by these molecules may not be long-lasting, as
no specific T-cell memory is generated. There is also a concern
for potential induction of T-cell anergy, as recruited T cells will
not receive appropriate co-stimulation. 
Donor lymphocyte infusion (DLI) and adoptive transfer of
antigen-specific cytotoxic T lymphocytes (CTLs) targeting
Epstein Barr virus (EBV) associated antigens can control hema-
tologic malignancies, and EBV-specific CTLs in particular repre-
sent a cost effective treatment modality for EBV-associated
post-transplant lymphomas and Hodgkin’s lymphoma.2-4
Recent advances in the field have allowed genetic modifica-
tions of T cells to provide robust, personalized T lymphocytes
that target specific tumor-associated antigens. In this review
article, we will discuss the development of the clinical grade
methodologies that allowed efficient gene transfer to T cells,
and how such gene transfer has armed T lymphocytes with
enhanced anti-tumor activity, while retaining an acceptable
safety profile.
Gene transfer to T lymphocytes
Gene transfer in human T lymphocytes can be accomplished
by several means (Table 1). DNA plasmids can be inserted by
electroporation or nucleoporation, and transgenic T cells can
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Modern chemotherapy regimens and supportive care have
produced remarkable improvements in the overall survival of
patients with hematologic malignancies. However, the
development of targeted small molecules, monoclonal anti-
bodies, and biological therapies that demonstrate greater
efficacy and lower toxicity remains highly desirable in hema-
tology, and oncology in general. In the context of biological
therapies, T-lymphocyte based treatments have enormous
potential. Donor lymphocyte infusion in patients relapsed
after allogeneic hematopoietic stem cell transplant pioneered
the concept that T lymphocytes can effectively control
tumor growth, and this was then followed by the develop-
ment of cell culture strategies to generate T lymphocytes
with selective activity against tumor cells. Over the past
decade, it has become clear that the adoptive transfer of ex
vivo expanded antigen-specific cytotoxic T lymphocytes pro-
motes sustained antitumor effects in patients with virus-
associated lymphomas, such as Epstein-Barr virus related
post-transplant lymphomas and Hodgkin’s lymphomas.
Because of this compelling clinical evidence and the con-
comitant development of methodologies for robust gene
transfer to human T lymphocytes, the field has rapidly
evolved, offering new opportunities to extend T-cell based
therapies. This review summarizes the most recent biologi-
cal and clinical developments using genetically manipulated
T cells for the treatment of hematologic malignancies. 
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ABSTRACT
then be selected based on the accompanying insertion of
drug resistance genes.5 Although relatively inexpensive, this
approach is not efficient as naked DNA only integrates in a
very low percentage of T cells. As a consequence, several
weeks of culture are required to reach sufficient numbers of
manipulated T cells for clinical use, which may significantly
compromise their capacity to survive long-term in vivo. In
addition, the inclusion of genes encoding antibiotic resist-
ance in T cells may generate immunogenicity to the pro-
teins produced, with premature elimination of these cells in
vivo.6 Gene delivery can also be achieved through gam-
maretroviral vectors, which have been used in the majority
of T-cell based clinical studies. These vectors can be manu-
factured on a large scale and they produce stable integration
into the genome of the T cell and its progeny, formed by cell
division. Current major concerns raised by the use of these
viruses are the risks of generating replication competent
retroviruses (RCR) and insertional mutagenesis. Modern
packaging cell lines have significantly reduced the risk of
generating RCR, as confirmed by a recent extensive analysis
of more than 800 samples collected from different trials in
the USA, all of which were free from RCR contaminants.7
Similarly, adverse consequences due to insertional mutage-
nesis in T cells have not yet been reported; a very different
safety profile compared to the use of these same vectors to
genetically modify hematopoietic stem cells.3,8,9 Lentiviral
vectors have also been recently used to engineer T cells in
non-HIV patients.10 These vectors are particularly attractive
when less differentiated T-lymphocyte phenotype needs to
be preserved, as they have the unique ability to infect T
cells even upon a minimal activation, a property lacking in
gammaretroviral vectors.11 Unfortunately, the large-scale
production of lentiviral vectors for clinical use remains
problematic. Novel non-viral methods to deliver genes into
T cells are based on transposon/transposase systems
(Sleeping Beauty12 and PiggyBac)13 which have a higher inte-
gration rate than naked DNA and allow the insertion of
larger fragments of DNA than many viral vectors. Clinical
trials using the Sleeping Beauty-based strategy to genetical-
ly modify T lymphocytes with a chimeric antigen receptor
have recently been approved by the US Food and Drug
Administration (FDA).
Donor lymphocyte infusions and suicide genes
Donor lymphocyte infusion (DLI) is the simplest form of
T-cell based immunotherapy after allogeneic hematopoietic
stem cell transplant (HSCT). DLIs have induced complete
remissions in relapsed patients with chronic myelogenous
leukemia (CML) and other hematologic malignancies.2,14
However, the graft-versus-leukemia (GVL) effect mediated
by T lymphocytes is frequently associated with a more gen-
eralized immune attack on the recipient known as graft-ver-
sus-host disease (GvHD). This complication remains a sig-
nificant cause of morbidity and mortality, especially if DLI
are obtained from donors who are non HLA-matched sib-
lings.15
The genetic manipulation of donor lymphocytes to incor-
porate a suicide gene for their prompt elimination upon
occurrence of severe GvHD represents an elegant approach,
and a study using the gene transfer of the Herpes Simplex
virus-derived enzyme thymidine kinase (HSV-tk) is now in
a phase III clinical trial.16,17 HSV-tk phosphorylates nucleo-
side analogs that ultimately inhibit DNA synthesis, thereby
killing dividing cells. This gene has been inserted in T lym-
phocytes to act as a suicide gene in the presence of gancy-
clovir (Figure 1). To date, more than 120 patients have been
infused with HSV-tk modified T cells after receiving
matched or haploidentical HSCT. None of these patients
had evidence of severe adverse effects from the transgene,
including those associated with insertional mutagenesis,
further underlining the safety of the gammaretroviral-medi-
ated gene transfer in T cells. When GvHD occurred, it was
efficiently controlled by the administration of gancyclovir
in all patients. Importantly, the infusion of HSV-tk modified
T cells had relevant clinical benefits since it improved the
rate of immune reconstitution, which is usually significant-
ly delayed following haploidentical HSCT, and appeared to
have anti-leukemic activity.17,18 The current phase III study
should provide definitive information concerning the effica-
cy of this treatment. Nonetheless, the use of HSV-tk modi-
fied T cells has some limitations. The first drawback is that
gancyclovir administration to these patients with the intent
to prevent or treat cytomegalovirus (CMV) reactivation can
not be accomplished without premature elimination of the
transgenic T cells, so that alternative and potentially more
toxic drugs are required to control infections or diseases
caused by this virus. Secondly, the elimination of HSV-tk T
cells by gancyclovir requires several days. As a conse-
quence, this suicide gene may not be highly efficient in
promptly controlling severe GvHD. Finally, there has been
evidence of immune responses against the HSV-tk gene,
leading to the elimination of transgenic T cells, especially
when these T cells are infused in patients with spontaneous
T-cell immune reconstitution.19 New variants of the HSV-tk
gene are currently being explored to avoid alternative splic-
ing that makes non-functional proteins.
At our institution, we have developed a novel suicide
gene based on the expression of an inducible caspase-9
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Table 1. Gene delivery systems for T cells.
Gene delivery Packaging Manufacturing Host Genomic integration Expression Clinical Safety concern
method capacity range frequency trials
Gammaretrovirus 4kb Good packaging cell line. Dividing cells High Long-term Yes Insertional
High titer. Expensive mutagenesis
Lentivirus 8kb Poor packaging cell line. Dividing and High Long-term Yes Potential
Low titer. Expensive non-dividing cells insertional
mutagenesis
Plasmids “Unlimited” Easy production. Dividing and Very low Transient Yes Unknown
Selection needed non-dividing cells
Transposone/ “Unlimited” Easy production. Dividing and Intermediate Long-term Yes Unknown
Transposase Selection needed non-dividing cells
(iC9) gene in T cells (Figure 1).20 The innovation of this sui-
cide approach relies on the expression of an inducible
human molecule (iC9) that activates the cell’s physiological
apoptotic pathway in response to a specific small molecule.
The native caspase-9 molecule that acts as a key player in
the mitochondrial apoptosis is modified to include a motif
that allows its dimerization (and hence activation) in the
presence of a chemical inducer of dimerization (CID)
(Figure 2).21 Unlike HSV-tk, the function of iC9 is not
dependent on cell cycle and allows the rapid (within a few
hours) induction of apoptosis in T cells. In a phase I dose
escalation clinical trial, 10 patients who had undergone hap-
loidentical HSCT received T cells expressing iC922 (MK
Brenner, unpublished data, 2012). As previously observed in
the HSV-tk clinical trials, infusion of iC9-modified T cells
was well tolerated up to 1x107 cells/kg, and induced rapid
immune reconstitution. Four patients who developed grade
I-II GvHD received a single intravenous infusion of CID
that determined the elimination of more than 90% of iC9-
T cells from the peripheral blood within 30 min of complet-
ing drug infusion, and complete and sustained resolution of
the GvHD. Non-alloreactive T cells expressing iC9 were
still detectable in the peripheral blood of patients more than
one year after infusion.22 This preliminary experience show-
ing the rapid induction of cell death in T lymphocytes
expressing the iC9 suicide in response to CID indicates that
this strategy may hold important advantages when com-
pared to HSV-tk. Clinical trials in other centers are currently
validating this approach. Two other suicide genes are based
on the expression of CD2023 and inducible CD95 (Fas).24
These approaches have not yet been tested clinically. While
the Fas-based approach relies on the same principle of the
iC9 system, the forced expression of CD20 by T lympho-
cyte provides the advantage of using a single molecule (anti-
CD20 antibodies) to select the transgenic cells in vitro and to
eliminate them in vivo. Although the simplicity of this
approach continues to make it an attractive option, CD20
antibodies such as rituximab will also deplete normal B
lymphocytes when they are infused to control GvHD
induced by CD20-transgenic T cells.
T lymphocytes with redirected specificity
The ex vivo generation of antigen-specific CTLs relies on
culture conditions in which polyclonal T cells isolated from
peripheral blood are progressively enriched for those recog-
nizing antigens loaded and presented by professional anti-
gen-presenting cells (APCs).25 Cultured CTLs are mostly
composed of effector-memory T lymphocytes, with cyto-
toxic activity (mediated by their TCRs) against tumor cells
expressing the antigens that have been presented by the
APCs ex vivo. Using this methodology, EBV-specific CTLs
have been successfully generated and expanded ex vivo, and
safely and effectively infused in over 100 patients to prevent
or treat EBV-associated malignancies.3,4 Although similar
strategies have been implemented to generate T cells target-
ing minor histocompatibility antigens26 or other relevant
tumor-associated antigens (TAAs) expressed by hematolog-
ic malignancies, such as survivin,27 hyaluronan-mediated
motility receptor (HMMR/Rhamm),28 Wilms tumor gene
product 1 (WT1),29,30 proteinase 1 (PR1),31 preferentially
expressed antigen in melanoma (PRAME)32,33 and MAGE,34
the production of these cells for clinical purposes remains
largely suboptimal due to its complexity and the low fre-
quency of CTLs with adequate TCR affinity.32
While the introduction of suicide genes provides the per-
fect example of how gene transfer contributes to dramati-
cally improving the safety of conventional DLI after allo-
geneic HSCT, gene transfer can also be used to reshape the
antigen specificity of T lymphocytes. Thus, polyclonal lym-
phocytes can be manipulated to express artificial antigen
receptors (chimeric antigen receptors CARs), or ectopic α-
and β-TCR chains, thereby conferring a second antigen
V. Hoyos et al.
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Figure 1. Expression of suicide genes in T lympho-
cytes. The figure illustrates the two suicide systems
that have been tested in clinical trials. (A) HSV-tk is
an enzyme that phosphorylates specific nucleoside
analogs (gancyclovir) to nucleoside monophos-
phate. A second cellular kinase phosphorylates this
product into nucleoside triphosphate, a molecule
that inhibits DNA synthesis and therefore leads to
death of dividing cells. (B) Caspase-9 is a key player
in the mitochondrial apoptosis pathway. This mole-
cule dimerizes upon binding with apaf1 and leads to
cleavage of the effector caspases 3, 6 and 7. (C) The
inducible caspase-9 (iC9) is a fusion protein in
which the native CARD domain has been replaced
by an FKBP12 domain that dimerizes in the pres-
ence of a specific chemical inducer of dimerization
(CID).
specificity to T cells in addition to their native TCR (Figure
3).35,36 Both strategies provide a means of generating large
numbers of T cells with defined antigen specificity that can
be used for adoptive T-cell immunotherapy trials, thus over-
coming the time consuming and highly inefficient process
of selecting and expanding T cells that are naturally reactive
against TAAs.
CAR-modified T lymphocytes
CARs are generated by fusing two distinct functional
fragments. The most widely used combination is the anti-
gen binding specific fragment composed of the single chain
(scFv) obtained from the variable domains of the heavy and
light chains of a monoclonal antibody, and the signaling
domain derived from the CD3ζ chain (Figure 3).35 These
simple molecules are currently defined as first generation
CARs, and when expressed by CD8 and CD4 T-cell sub-
sets, they provide specific binding to antigens expressed on
the cell surface of tumor cells and simultaneous activation
of the cytotoxic machinery (granzyme-B and perforin) of T
cells through the CD3ξ chain signaling immunoreceptor
tyrosine-based activation motif (ITAM). Due to the anti-
body-mediated antigen recognition, the cytotoxic function
of CAR-redirected T cells does not depend on the canonical
antigen processing and MHC-restricted presentation typical
of native TCRs. However, several pre-clinical models
showed that first generation CARs do not fully activate
modified T cells upon engagement with the antigen, as
these molecules lack co-stimulatory properties. To over-
come this obstacle, second generation CARs have been gen-
erated in which intracytoplasmic domains, derived from co-
stimulatory molecules such as CD2837,38 or CD134/OX4039
or CD137/4-1BB,40 are incorporated within CARs to fully
activate T cells. Third generation CARs, in which two co-
stimulatory molecules (CD28 and 4-1BB or CD28 and
OX40)39,41 are encoded in tandem, have also been generated,
and pre-clinical experiments suggest that these molecules
may be even more potent than second generation CARs
(Figure 3).
T lymphocytes expressing CD19- and CD20-specific CARs
For hematologic malignancies, CAR technology allows
targeting of lineage restricted antigens, such as CD1942 and
CD2043 that are conserved in the malignant counterpart, by
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Figure 2. Inducible caspase 9 suicide gene. (A) Schematic representation of the bicistronic vector that encodes the inducible caspase 9 (iC9)
and the truncated form of human CD19. The two genes are linked through the inclusion of a 2A-like peptide sequence. (B) Expression of
CD19 in activated T lymphocytes transduced with the bicistronic vector and enrichment of CD19+ cells obtained after positive selection using
a CD19-specific antibody. (C) Induction of apoptosis of T cells 24 h after exposure to the AP1903 (CID) that activates the inducible caspase
9. (D) Elimination of transduced T cells in 4 patients after one single dose of AP1903 as measured by phenotypic analysis and copy numbers
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combining the binding specificity from the available mono-
clonal antibody targeting these surface molecules with the
potent effector function of T lymphocytes. More than 20
clinical trials have been registered in the USA for infusing T
lymphocytes expressing CD19- or CD20-specific CARs in
patients with B-cell derived malignancies,44 and results from
many of these studies have recently been reported (Table
2).5,10,45-49 When analyzing the results of these trials, it is
important to appreciate that few patients have so far been
enrolled in each study, and each study cohort is heteroge-
neous with regards to patient age and type/stage of disease.
There is also heterogeneity in the CAR constructs in terms
of the co-stimulatory endodomains used, and the gene
transfer systems and culture conditions employed to gener-
ate and expand these CAR-modified T cells. Although these
variables make study comparisons difficult, it is possible to
extrapolate guidelines for future applications of this tech-
nology: a) infusions of CAR-modified T cells are generally
well tolerated, with only one serious reported adverse event
which may, however, not have been directly associated
with the T-cell infusion;50 b) virus-mediated gene transfer
seems to be the most efficient gene delivery method, as it
allows robust expression of CARs by T cells, and minimizes
the time of their ex vivo culture; c) the incorporation of co-
stimulatory endodomains (CD28 or 4-1BB) within CARs is
essential in supporting their in vivo persistence;10,45 d) trials
that include lymphodepleting chemotherapy regimens
prior to the T-cell infusion may have better clinical out-
comes, as they reduce the tumor burden and provide an
environment for the infused T cells that favors homeostatic
expansion.48 For example, impressive results were reported
in 3 patients with aggressive, heavily pre-treated chronic
lymphocytic leukemia (CLL) who received chemotherapy
1-4 days prior to the infusion of T cells transduced with a
lentiviral vector encoding a CD19-specific CAR, incorporat-
ing the 4-1BB co-stimulatory endodomain.10 In this trial, the
infused cells showed logarithmic expansion in vivo and
migration to the site of disease with remarkable cytotoxic
effects against tumor cells (2 complete and one partial
remission), and persistence for more than 180 days. In con-
trast, CAR-T cell expansion observed in vivo in clinical trials
using CD19-specific CARs that incorporate the CD28 sig-
naling endodomain have produced less striking results,45
suggesting that the ‘late activation’ signaling pathways
recruited by 4-1BB may be critical for functional, long-term
expansion and engraftment of CAR-redirected T cells.
However, given the diversity of the trials developed so far,
systematic assessment of whether 4-1BB is responsible for
the better outcome observed in one clinical trial may
require a formal comparison between CAR-T cells encod-
ing CD28 and CAR-T cells encoding 4-1BB infused in the
same patient, in a similar way to the direct comparison of
first and second generation (CD28 co-stimulation) CD19-
specific CAR reported previously.45
Several significant issues still remain to be resolved before
designing large phase II studies using CAR technology. 
Is the current design of CAR molecules ideal? Potent third
generation CARs have been generated to combine ‘early’
(CD28) and ‘late’ co-stimulatory signals (4-1BB or OX40)
for complete T-cell activation.39,41 However, combinations of
these molecules raise safety concerns since they may induce
T cells to produce excessive amounts of cytokines and pro-
mote severe cytokine storms as observed in a patient treat-
ed at the National Cancer Institute.51 One trial has been
published using a CD19-specific third generation CAR
(CD28 and 41BB).52 The infusion of these cells did not pro-
duce significant side effects, but the CAR for this study was
delivered in T cells by DNA electroporation, and required
extensive ex vivo culture before infusion, which may
exhaust these T cells and thus underestimate their potential
toxicities. Many CARs may also be immunogenic, as the
scFv are usually derived from mouse hybridomas. Although
CAR-T cells can still be detected for months after infusion,
humanized scFv may be preferable in the future to reduce
the immunogenicity.
How much lymphodepletion is required before the infu-
sion of CAR-modified T cells? Regimens inducing profound
lymphodepletion used by the group at the National Cancer
Institute are based on their experience in melanoma
patients infused with tumor infiltrating lymphocytes.36,48,53
However, because significant clinical responses were
obtained in patients infused with CAR-T cells after less pro-
V. Hoyos et al.
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Figure 3. Redirecting T-cell speci-
ficity. T-cell specificity can be
redirected by the expression of
chimeric antigen receptors
(CARs) or transgenic α- and β-
TCR chains. (A) CARs are com-
posed of two distinct fragments.
The first is obtained by linking
the variable heavy and light
regions of a monoclonal antibody
of known specificity into a single
chain (scFv) and the second is
the signaling region of the native
TCR ζ-chain. (B) Second genera-
tion CARs incorporate co-stimula-
tory molecules such as CD28
and 4-1BB. (C) Third generation
CARs include 2 or more co-stim-
ulatory molecules. (D) CARs are
activated after the scFv portion
binds to an extracellular antigen
thus the antigen recognition is
MHC-independent. (E) Transgenic
TCRs recognize specific peptides
presented in the context of MHC
class I molecules.
found immunodepletion induced by treatment with flu-
darabine, bendamustine or pentostatin, profound lym-
phodepleting regimens may not be necessary if robust co-
stimulation is provided to CAR-modified T cells.10
Are all B-cell malignancies susceptible to control by
CD19-specific CAR-T cells and which stage of disease
should be targeted? Chronic lymphocytic leukemias and
low-grade lymphomas appear highly responsive to CAR-
mediated immunotherapies,10,48,54 while relapsed/refractory
high-grade lymphomas are rarely controlled,45,48 likely due
to the more rapid progression of the latter. We still lack data
from clinical trials targeting acute leukemia. Of note, tumor
lysis syndrome has been observed in responding patients
with bulky or advanced stage diseases,10 suggesting that
CAR-T cell-based therapy may be better suited to minimal
residual disease or as an adjuvant for patients at high risk of
relapse, who respond to salvage treatment or after trans-
plant. In this regard, our group recently initiated a phase I
clinical trial in patients with B-cell malignancies who had
relapsed after allogeneic HSCT. In this trial, patients are
infused with donor-derived CTLs specific for opportunistic
viruses (CMV, EBV and adenoviruses) that have also been
genetically modified to express a CD19-specific CAR.55,56
The aim of this study is to provide a T-cell product that
simultaneously protects against viral infection and produces
anti-leukemia activity, without causing GvHD. In addition,
virus specificity should promote the long-term persistence
of these cells, following physiological activation and co-
stimulation when their native TCRs engage latent virus
(EBV and CMV)-associated antigens presented by profes-
sional APCs.57 So far, infusions of these products have been
well tolerated without occurrence of GvHD or viral infec-
tions in 3 patients.
Other CARs for hematologic malignancies
While targeting CD19/CD20 by CAR-modified T cells
may have benefit for B-cell derived malignancies, long-term
persistence of CD19-specific CAR-T cells is associated with
elimination of normal B lymphocytes, with resulting
impairment of humoral immunity.10 Although this compli-
cation may be compensated by the administration of
pooled immunoglobulins, more selective CARs targeting B-
cell associated antigens have been generated that eliminate
tumor cells while sparing normal B lymphocytes. For exam-
ple, mature B-cell malignancies express monoclonal
immunoglobulins carrying either the λ- or κ-light chain.
Our group, therefore, developed a CAR that targets the κ-
light chain, and demonstrated that T cells expressing this
CAR can eliminate leukemic and normal κ-restricted B cells
whilst sparing normal λ-chain restricted B lymphocytes,
thus preserving at least a subset of the normal B-cell com-
partment.38 A phase I clinical trial using this approach is
open at our institution. Alternative selective targets for B-
cell malignancies that have been explored in pre-clinical
models include CD23,58 CD7059 and ROR1.60 CD23, a B-cell
activation marker, is highly expressed by CLL cells but only
at relatively low levels in normal B lymphocytes. Pre-clinical
studies have confirmed that CD23-CAR redirected T cells
Table 2. Results of clinical trials using CARs targeting CD19 and CD20.
Reference Targeted Construct/ Gene Cell Concomitant Cell N. Outcomes CAR-T cell
disease/ generation transfer activation therapy dose patients persistence
antigen
Till et al.5 B-NHL/CD20 scFv- Electroporation OKT3 Cyclophosphamide 1x108/m2 7 2 maintained 1-3 weeks
CH2CH3 - or fludarabine to 3.3x109/m2 CR alone./5-9
CD4TM -CD3ζ +/- IL-2 1 PR, 4 SD weeks with
First IL-2
Jensen et al.6 NHL/CD19 or scFv- CH2CH3 Electroporation OKT3 ASCT/fludarabine 5 at 4 2 maintained CR 1-7 days,
CD20 -CD4TM -CD3ζ IL-2 108/m2, after ASCT cellular
First 7 at 109/m2, immune
3 at 2x109/m2 response 
against 
CAR-T cells
Savoldo et al.45 NHL/CD19 scFv- CH2CH3 Gammaretrovirus OKT3/CD28 None 2x107/m2 6 2 SD Persistence of
-CD3ζ to 2x109/m2 second 
First vs. generation
scFv- CH2CH3 for more than
-CD28-CD3ζ 6 months
Second
Brentjens et al.46 CLL or scFv-CD28-CD3ζ Gammaretrovirus CD3/CD28 Cyclophosphamide 1.2-3x107/m2 10 1 Death, 3 SD 40 days
ALL/CD19 Second Beads then 0.4-1x107/m2
Kalos et al.10 CLL/CD19 scFv-41BB-CD3ζ Lentivirus CD3/CD28 Bendamustine 1.4x107 /m2 to 3 2 CR, 1 PR >6 months
Porter et al.47 Second Beads or pentostatin/ 1.1x109/m2 >1,000-fold 
cyclophosphamide expansion 
of CAR-T cells
Kochenderfer B-NHL/CLL/ scFv-CD28-CD3ζ Gammaretrovirus OKT3 Cyclophosphamide/ 0.5-5.5x107/Kg 8 6 PR, 1 CR,1 SD 14 weeks
et al.48 CD19 Second fludarabine
IL-2
Till et al.49 B-NHL/CD20 scFv- CH2CH3 Electroporation OKT3 Cyclophosphamide 1x108/m2 to 4 2 SD, 2 PR 12 months
-CD4TM CD28- IL-2 3.3x109/m2
41BB- CD3ζ
Third
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can control CLL growth in vitro and in vivowith minimal tox-
icity to normal B lymphocytes.58 CD70 is the ligand of
CD27 receptor and is only transiently expressed by highly
activated T and B cells, as well as by dendritic cells, but
aberrantly over-expressed by many leukemias and lym-
phomas.59 The CD70-specific counter receptor CD27 has
been fused to the CD3ζ chain and expressed by T lympho-
cytes, resulting in the elimination of CD70-expressing lym-
phoma cells.59 The receptor tyrosine kinase-like orphan
receptor 1 (ROR1) is highly expressed in CLL and mantle
cell lymphoma cells. Unlike CD23 and CD70, expression of
ROR1 is not up-regulated with B-cell activation, and expres-
sion in non-hematopoietic tissues is limited to adipose tis-
sue, immature B cells and pancreas. ROR1-CAR redirected
T cells are cytotoxic to CLL cells, and ongoing studies in
non-human primates are addressing the potential toxicities
of this strategy, especially in view of shared expression by
pancreatic cells.60
CD30 antigen is also being targeted by CAR-redirected T
cells in an effort to extend the application of the technology
to non-B cell lymphomas.61,62 CD30 is aberrantly expressed
by most Hodgkin’s and some non-Hodgkin’s lymphomas.
CD30 has been validated as a therapeutic target since mon-
oclonal antibodies directed to this antigen have produced
objective clinical responses.63 CD30-specific CARs have also
been extensively evaluated in pre-clinical studies, and two
clinical trials with CD30-CAR redirected T cells in CD30+
lymphoma patients are currently open at our institution. For
the treatment of myeloid malignancies, a CD33-specific
CAR has been developed.64 Although effective in pre-clini-
cal experiments, this approach needs further evaluation as
CD33 is a pan-myeloid marker, and CD33-CAR redirected
T cells may, therefore, lead to profound and prolonged
myeloid depletion. The isoform variant 6 of CD44
(CD44v6) represents another possible target for CAR-T
cells in myeloid leukemias and in myeloma. Preliminary
results show that CD44v6-CAR redirected T cells had anti-
tumor effects against CD44v6+ malignancies.65 However,
the expression of this antigen by keratinocytes and the skin
toxicity reported in patients treated with the corresponding
monoclonal antibody are a potential cause for concern.66
T lymphocytes expressing ectopic α- and β-TCR chains
The antigen specificity of T lymphocytes can also be redi-
rected by the expression of a second TCR with known
specificity. This is the only strategy available to target intra-
cytoplasmic proteins that are processed and presented in
association with MHC molecules (Figure 3). This category
includes the great majority of tumor-associated/cancer
testis antigens. For this approach, the antigen-specific TCR
is usually derived from human T-cell clones with high affin-
ity for the specific epitope or from murine T cells obtained
by immunization of HLA-2 transgenic mice. Transgenic
TCR chains can be expressed in polyclonally activated T
cells, to provide them with a second HLA-restricted tumor
specificity in addition to the native antigen specificity
(Figure 3). This strategy has been pioneered by the group at
the National Cancer Institute, in patients with melanoma or
other solid tumors by targeting MART-1 and NY-ISO anti-
gens.36,67 Complete and sustained clinical responses have
been observed in these patients. For hematologic malignan-
cies, transgenic TCRs have been prepared that target the
Wilms tumor gene product 1 (WT1), which is a zinc finger
transcriptional regulator present in acute myeloid leukemia,
CML and myelodysplastic syndome.30 A phase I clinical trial
using this approach is currently ongoing in Europe and, if
successful, this approach can be extended to many antigens
that are highly expressed in leukemia or lymphomas, such
as hyaluronan-mediated motility receptor
(HMMR/Rhamm), melanoma antigen preferentially
expressed in tumors (PRAME), proteinase 3 (PR3), MAGE-
antigens and survivin. 
Unlike CARs, the cytotoxic activity of transgenic TCRs
remains HLA-restricted, and the great majority of cloned
TCRs are HLA-A2 restricted, since this is the most frequent
polymorphism in Caucasians. However, since technologies
are now available to screen immunodominant epitopes
presented by other HLA antigens, cloned TCRs will soon
be available for many more HLA molecules. A concern
associated with the ectopic expression of TCR in T lym-
phocytes is mispairing between native and transgenic α-
and β-chains. This event reduces the expression of desired
TCR (loss of function) and may also create unknown TCR
specificities with potential autoreactivity (gain of function).
Although animal models have shown that this mispairing
can have off-target effects,68 no such side effects have yet
been observed in patients. However, strategies to enhance
the expression of transgenic TCR or to silence the endoge-
nous TCR have been developed to minimize this con-
cern.69-71
Enhancing persistence and trafficking 
of tumor-specific T lymphocytes
T cells with defined antigen-specificity are a fundamental
requirement for T-cell based therapies of human malignan-
cies. Once infused, T cells must accomplish several other
tasks to achieve robust and sustained tumor regression. For
instance, adoptively transferred T cells must expand and
persist to reach the critical mass required to eliminate the
tumor, in a similar way to their activity against pathogens.
T cells must also reach the tumor site, and overcome the
inhibitory mechanisms developed by tumor cells to block
immune responses. It is likely that the clinical efficacy of
adoptively transferred antigen-specific T cells will be
enhanced by combination with systemic immunomodula-
tory molecules, such as the check-point modulators CTLA-
4 or PD-1 blocking antibodies.72 However, to avoid the non-
specific toxic effects of these antibodies produced by
enhancing autoreactive clones, the clinical benefits of adop-
tively transferred T cells can be enhanced by incorporating
genes into the modified cells that optimize their persist-
ence, tumor-trafficking and resistance to tumor-mediated
immunosuppression (Figure 4). 
Ex vivo expanded T cells are highly dependent on
cytokines for their continued growth and survival. To over-
come the frequent toxicities associated with the systemic
administration of cytokines such as IL-2, genetic modifica-
tions have allowed T cells to produce their own IL-273,74 or
IL-15,73,75 or to respond to homeostatic cytokines such as IL-
7 through the constitutive expression of IL-7Rα.76 These
modifications enhance anti-tumor effects in pre-clinical
models. T-cell trafficking to the tumor microenvironment
can also be improved. For example, specific chemokine
receptors can be ectopically expressed by T cells to improve
their homing along the chemokine gradients produced by
tumor cells. This approach is effective in pre-clinical models
of melanoma, Hodgkin’s lymphoma, and neuroblastoma in
which overexpression of CXCR2,77 CCR478 or CCR2b79 by
T cells enhanced their trafficking (and subsequent anti-
tumor effects) along CXCL1, TARC and CCL2 gradients,
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respectively. Genetic modifications have also been exploit-
ed to counter inhibitory molecules present in the tumor
microenvironment. T cells can be rendered resistant to
transforming growth factor beta (TGF-β) by the expression
of a dominant-negative TGF-β type II receptor (dnTGF-β
II),80,81 or to be resistant to Fas ligand-induced apoptosis by
selective downregulation of Fas/CD95.82 IL-12 secretion83,84
or/and expression of constitutively active Akt (caAkt)85 by T
cells also overcome an immunosuppressive tumor environ-
ment, and clinical trials evaluating the effects of expressing
dnTGF-β II or IL-12 in T cells are ongoing. In patients
receiving treatments that inhibit T-cell function, it is also
possible to give antigen-specific T cells that are engineered
to be resistant to the administered agent. For example, anti-
gen-specific T cells can be made resistant to immunosup-
pressive drugs such as FK506,86 cyclosporine87 and
rapamycin,88 and used to reconstitute anti-EBV specificity in
transplant recipients at risk of PTLD or in combination with
rapalogs in lymphoma patients.
Conclusions
Cure of many cancers, including hematologic malignan-
cies, will require the combination of multiple therapeutic
approaches, including adoptive T-cell immunotherapy,
which will likely become a key player in integrated and per-
sonalized cancer therapy. T cells with redirected antigen
specificity are one of the most attractive approaches, and it
is likely that the clinical efficacy of redirected T cells will be
further enhanced by the addition of multiple genetic modi-
fications. However, such potent T cells can also induce dra-
matic and even lethal adverse effects, and therefore the anti-
gens targeted and the activation signals incorporated in the
T cells need careful evaluation. The inclusion of safety
switches as an 'exit strategy' can also be considered to min-
imize damage to normal tissues. The many developments
in this field, the striking clinical outcomes and the introduc-
tion of simpler, cheaper and faster methods to generate
these genetically modified T cells should all help insure they
will make a major contribution to the battle against hema-
tologic malignancies.
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Figure 4. Enhancing T-cell persistence and traffick-
ing. The figure illustrates some of the genetic mod-
ifications that have been implemented with the
purpose of improving the anti-tumor effects of
adoptively transferred T cells. (A) Expression of
constitutively activated Akt (caAkt) supports
cytokine production and upregulation of anti-apop-
totic molecules in T cells. (B) IL-7Rα expression
that is lost in effector-memory T cells can be
restored rendering effector-memory T cells respon-
sive to the homeostatic cytokine IL-7. (C) T cells
can be modified to produce cytokine such as IL-2,
IL-15 and IL-12 to support their own proliferation
and function. (D) CD95(Fas) that leads to apopto-
sis of activated T lymphocytes by engaging its lig-
and Fas-L can be down-regulated by siRNA in T
cells in order to provide them with resistance to
Fas-L-mediated apoptosis. (E) T cells genetically
modified to express a dominant negative TGF-β
receptor (dnTGF-βII) are resistant to TGF-β inhibi-
tion. (F) T cells forced to express specific
chemokine receptors show enhanced migration
towards tumor chemokine gradients. 
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